This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
To report the results of presbyopia-correcting intraocular lenses (IOLs) implantation in patients with Fuchs endothelial corneal dystrophy (FECD).
A retrospective, case-control study of FECD patients that were implanted with presbyopia-correcting IOLs. The results were compared with a matched group of patients at a case-control ratio of 1:3. Endothelial cell count, uncorrected distance visual acuity (UCDVA), uncorrected intermediate visual acuity (UCIVA), uncorrected near visual acuity (UCNVA) and post-operative refraction were analyzed.
A total of 19 eyes of 10 patients with FECD were included in the study (mean endothelial cell count 1323.52±767.54 cells/mm2). No significant difference between FECD patients and the control group were found in the UCDVA (LogMAR) (mean 0.11±0.13 and 0.06±0.10, P=0.12, respectively), UCIVA (LogMAR) (mean 0.11±0.11 and 0.10±0.12, P=0.98, respectively) and post-operative refraction outcomes (mean spherical equivalent (SE) (D) 0.14±0.31 and -0.21±0.24, P=0.31, respectively).The UCNVA (LogMAR) was better among the FECD patients, 0.03±0.05 compared to 0.15±0.18 in the control group (P=0.009).
Our results suggest that presbyopia-correcting IOLs can be considered in patients with FECD, with clear corneas, that are not candidate for corneal transplantation.